Cargando…
The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study
SIMPLE SUMMARY: Radium-223 is an alpha-emitting radioisotope that selectively binds to increased bone turnover areas, such as metastatic sites, acting as a bone-seeking calcium mimetic drug. Its therapeutic function in metastatic castration-resistant prostate cancer patients relies on its capability...
Autores principales: | Bauckneht, Matteo, Rebuzzi, Sara Elena, Signori, Alessio, Donegani, Maria Isabella, Murianni, Veronica, Miceli, Alberto, Borea, Roberto, Raffa, Stefano, Damassi, Alessandra, Ponzano, Marta, Catalano, Fabio, Martelli, Valentino, Marini, Cecilia, Boccardo, Francesco, Morbelli, Silvia, Sambuceti, Gianmario, Fornarini, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693606/ https://www.ncbi.nlm.nih.gov/pubmed/33142739 http://dx.doi.org/10.3390/cancers12113213 |
Ejemplares similares
-
Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223
por: Bauckneht, Matteo, et al.
Publicado: (2019) -
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223
por: Bauckneht, Matteo, et al.
Publicado: (2022) -
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)
por: Bauckneht, Matteo, et al.
Publicado: (2021) -
Beyond the Prognostic Value of 2-[(18)F]FDG PET/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management
por: Borea, Roberto, et al.
Publicado: (2022) -
Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study
por: Bauckneht, Matteo, et al.
Publicado: (2022)